Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Mitochondrial dynamics / bioenergetics: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| CGAS | participates_in | gene | 0.54 |
| STING1 | participates_in | gene | 0.54 |
| DNASE2 | participates_in | gene | 0.54 |
| COX4I1 | participates_in | gene | 0.47 |
| TFAM | participates_in | gene | 0.46 |
| MIRO1 | participates_in | gene | 0.43 |
| RAB27A | participates_in | gene | 0.41 |
| GJA1 | participates_in | gene | 0.41 |
| SYNCRIP | participates_in | gene | 0.40 |
| GAP43 | participates_in | gene | 0.38 |
| ALOX5 | participates_in | gene | 0.36 |
| TRAK1_KIF5A | participates_in | gene | 0.34 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.570
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.490
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.552
neurodegeneration | 2026-04-01 | 8 hypotheses Top: 0.703
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.554
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk Cohorts | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Mixed Pathology Effects on Parkinson's Disease Progression and Treatme | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Traumatic Brain Injury and Alzheimer's Disease Relationship | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Viral Infections and Alzheimer's Disease — causal mechanisms and thera | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Viral and Post-Infectious Mechanisms in ALS — Experiment Design | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Regulated Necrosis Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| NLRP3 Inflammasome Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| cGAS-STING Pathway Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Biomechanical Impact Profiles and Chronic Traumatic Encephalopathy Phe | clinical | Neurodegeneration | 0.400 | 0.50 | in_silico | proposed | $180,000 |
| Wilson Disease Neurodegeneration: Mechanism and Therapeutic Response | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $7,500,000 |
| GLP-1 Agonist Neuroprotection Mechanism in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Prodromal Parkinson's Disease Biomarker Development — Early Detection | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Synaptic Mitochondrial Resilience Enhancement for Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Peroxisomal Dysfunction Validation in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Cytochrome Therapeutics | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Ferroptosis Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinso | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
| s:** - Test MCU overexpression specifically in layer II neurons in hea | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $200,000 |
| Proposed experiment from debate on Mitochondrial transfer between astr | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Organelle-specific autophagy in inflammatory diseases: a potential therapeutic t [PMID:32048886] | Yao RQ, Ren C, Xia ZF, Yao YM | Autophagy | 2021 | 2 |
| TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS [PMID:33031745] | Yu CH, Davidson S, Harapas CR, Hilton JB | Cell | 2020 | 2 |
| Allosteric properties of mammalian ALOX15 orthologs. [PMID:41654134] | Yang J, Borchert A, Kuhn H | J Biol Chem | 2026 | 1 |
| Astrocytic Connexin43 in Alzheimer's disease: mechanisms, interaction with P2 re [PMID:41062060] | Xiong W, Su Y, Verkhratsky A, Yi C | Neuropharmacology | 2026 | 1 |
| Connexin43 hemichannel blockade turns microglia neuroprotective and mitigates co [PMID:40595567] | Su Y, Li H, Zhang W, Tao S, Wang Q, Zhan | Nat Commun | 2025 | 1 |
| Imp/IGF2BP and Syp/SYNCRIP temporal RNA interactomes uncover combinatorial netwo [PMID:39919181] | Lee JY, Huang N, Samuels TJ, Davis I | Sci Adv | 2025 | 1 |
| Miro1: A potential target for treating neurological disorders. [PMID:40403957] | Zeng L, Yang J, Zhang C, Zhu J, Zhong S, | Neuroscience | 2025 | 1 |
| SBFI26 induces triple-negative breast cancer cells ferroptosis via lipid peroxid [PMID:38516826] | He G, Zhang Y, Feng Y, Chen T, Liu M, Ze | J Cell Mol Med | 2024 | 1 |
| Should it stay or should it go: gap junction protein GJA1/Cx43 conveys damaged l [PMID:39394955] | Domingues N, Ribeiro-Rodrigues T, Girão | Autophagy | 2024 | 1 |
| Connexin 43 regulates intercellular mitochondrial transfer from human mesenchyma [PMID:39390589] | Irwin RM, Thomas MA, Fahey MJ, Mayán MD, | Stem Cell Res Ther | 2024 | 1 |
| Calcium-Associated Proteins in Neuroregeneration. [PMID:38397420] | Lisek M, Tomczak J, Boczek T, Zylinska L | Biomolecules | 2024 | 1 |
| Mitochondria from osteolineage cells regulate myeloid cell-mediated bone resorpt [PMID:38877020] | Ding P, Gao C, Zhou J, Mei J, Li G, Liu | Nat Commun | 2024 | 1 |
| Melatonin attenuates sepsis-induced acute kidney injury by promoting mitophagy t [PMID:37651673] | Deng Z, He M, Hu H, Zhang W, Zhang Y, Ge | Autophagy | 2024 | 1 |
| TFAM is an autophagy receptor that limits inflammation by binding to cytoplasmic [PMID:38783142] | Liu H, Zhen C, Xie J, Luo Z, Zeng L, Zha | Nat Cell Biol | 2024 | 1 |
| RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoi [PMID:37085479] | Herrejon Chavez F, Luo H, Cifani P, Pine | Nat Commun | 2023 | 1 |
| Tumour extracellular vesicles and particles induce liver metabolic dysfunction. [PMID:37225988] | Wang G, Li J, Bojmar L, Chen H, Li Z, To | Nature | 2023 | 1 |
| Extracellular vesicles in fatty liver promote a metastatic tumor microenvironmen [PMID:37172577] | Wang Z, Kim SY, Tu W, Kim J, Xu A, Yang | Cell Metab | 2023 | 1 |
| Selective inhibition of cannabinoid CB(1) receptor-evoked signalling by the inte [PMID:37689260] | Maroto IB, Moreno E, Costas-Insua C, Mer | Neuropharmacology | 2023 | 1 |
| Increased mitophagy protects cochlear hair cells from aminoglycoside-induced dam [PMID:35471096] | Zhang Y, Fang Q, Wang H, Qi J, Sun S, Li | Autophagy | 2023 | 1 |
| lncRNA LOC100911717-targeting GAP43-mediated sympathetic remodeling after myocar [PMID:36684596] | Li P, Wang K, Yin J, Qi L, Hu H, Yang P, | Front Cardiovasc Med | 2022 | 1 |